INTRODUCTION
============

The Lyme disease spirochete, *Borrelia burgdorferi*, persists in nature through infectious cycles between vertebrate hosts and *Ixodes* spp. tick vectors. Human infection is generally accompanied by an expanding 'bull's-eye'-shaped rash and nonspecific symptoms such as fever, aches and malaise. Untreated, *B. burgdorferi* infections may manifest as significant inflammatory arthritis, carditis and/or neurological disorders ([@B1],[@B2]).

*Borrelia burgdorferi* produces proteins that are specific for each stage of its vertebrate-arthropod infectious cycle. Among these are the Erp proteins, a polymorphic family of surface-exposed outer membrane lipoproteins that are highly expressed during all stages of mammalian infection but largely repressed during tick colonization ([@B3],[@B4]). Among the known functions of Erp proteins are adherence to host laminin and the binding of host plasminogen, complement regulator factor H and the factor H-related proteins FHR-1, FHR-2 and FHR-5 ([@B5; @B6; @B7; @B8; @B9; @B10; @B11; @B12; @B13; @B14; @B15]). These infection-associated functions make Erp proteins attractive targets for developing new protective and curative therapies for Lyme disease.

All Lyme disease spirochetes naturally contain multiple, distinct 32-kb circular prophages, collectively called cp32s ([@B3],[@B16]). Each cp32 contains a mono- or bicistronic *erp* locus. Nine different *erp*-containing cp32s are present in the *B. burgdorferi* type strain, B31 ([@B16; @B17; @B18]). A 10th *erp* locus is found in strain B31 on a mutant cp32 known as lp56, an ∼56-kb linear plasmid that consists of an entire cp32 integrated into an unrelated linear replicon ([@B17; @B18; @B19]). Another natural plasmid of strain B31, named cp9-1, evolved from a cp32 through a series of deletion and rearrangement mutations, and no longer carries an *erp* locus ([@B18]).

All *erp* loci contain highly conserved DNA sequences 5′ of the open reading frames ([Figure 1](#F1){ref-type="fig"}A). Genetic and biochemical studies revealed that two small regions 5′ of *erp* loci contain binding sites for *B. burgdorferi* cytoplasmic proteins ([@B20]). The DNA region closest to the transcriptional start site, Operator 2, appears to play a role in transcriptional regulation, as deletion of that sequence resulted in constitutive, high-level transcription ([@B20]). DNA-affinity chromatography indicated that at least three proteins specifically bind to *erp* 5′ DNA ([@B21]). We previously identified one of these as EbfC, which is a novel type of DNA-binding protein that is encoded on the borrelial main chromosome. EbfC preferentially binds the palindromic sequence GTnAC, where '*n*' can be any base, with all *erp* Operator 2 regions containing two adjacent EbfC-binding sites ([@B21],[@B22]). We now report identification and characterization of a family of closely related borrelial proteins named BpaB (*[B]{.ul}*orrelial *[Pa]{.ul}*r*[B]{.ul}* analog) that also bind *erp* Operator 2 DNA. All cp32 family members encode a BpaB protein, which appears to play a role in replication and segregation, possibly analogous to the ParB DNA-binding proteins of low copy-number plasmids in other bacterial species ([@B18],[@B23; @B24; @B25; @B26; @B27; @B28; @B29]). Predicted protein sequences of BpaB proteins are distinct from any known plasmid partition-segregation protein, and may represent a novel type of such proteins ([@B18],[@B24],[@B28]). Some species' ParB proteins are known to also be involved in plasmid gene regulation, by binding specific DNA sites and occluding promoter elements ([@B23],[@B30; @B31; @B32; @B33]). We therefore analyzed the DNA-binding characteristics of BpaB proteins encoded by cp32 family members. Figure 1.(**A**) DNA sequences 5′ of all known *erp* loci of *B. burgdorferi* strains B31, N40 and 297, indicating transcriptional promoter motifs, start of transcription (+1), the maximal borders of Operator 2 and two EbfC-binding sequences. Identical nucleotides found in the majority of known *erp* loci are boxed and shaded. For some *erp* loci of strain N40, only parts of some 5′ sequences are known, as indicated by blanks on this figure. These three strains, plus *B. burgdorferi* strain BL206 and Sh-2-82, are the only Lyme disease spirochetes for which the complete *erp* locus sequences have been published. The *erp* locus sequences of strain BL206 are identical to those of strain B31, and those of Sh-2-82 are identical to the *erp* loci of strain 297, and so were omitted from this figure (our unpublished data and references 18, 40, 43 and 44). (**B**) DNA sequences of biotin- and radiolabeled DNA probes used in EMSA studies. Base pairs present in the wild-type probe (b-WT) but absent from probe b-672 are indicated by a line. The DNA sequence identified as including the initial BpaB-binding site through studies illustrated in [Figure 5](#F5){ref-type="fig"} are shown on the lower line. All EMSA probes and competitors were double-stranded DNAs; for simplicity, only one strand (5′ to 3′) is illustrated.

MATERIALS AND METHODS
=====================

Bacteria
--------

The *B. burgdorferi* type strain, B31, was the original source for all DNAs and recombinant proteins used in these studies. The complete genome sequence of a subculture of strain B31, known as B31-MI, has been determined ([@B18],[@B34]). Strain B31-MI contains nine cp32 family members: cp32-1, cp32-3, cp32-4, cp32-6, cp32-7, cp32-8, cp32-9, cp9-1 and lp56. Two additional cp32 replicons, cp32-2 and cp32-5, have been found in other subcultures of the original B31 isolate, and have been partially sequenced ([@B16],[@B17]). A 12th cp32 family member, cp9-2, was identified in another B31 derivative, but its probable *bpaB* locus has yet to be sequenced ([@B35]).

Modeling analyses
-----------------

Primary amino acid sequences of proteins were compared with all known sequences in the nonredundant protein sequence database of GenBank using BLAST-P and Psi-BLAST (<http://www.ncbi.nlm.nih.gov/BLAST>). Protein folding probabilities were determined using Protein Homology/analogY Recognition Engine (PHYRE) ([http://www.sbg.bio.ic.ac.uk/∼phyre](http://www.sbg.bio.ic.ac.uk/~phyre)). Predictions of disorder within proteins were determined using Predictor of Naturally Disordered Regions (PONDR, [www.pondr.com](www.pondr.com)) using VL-XT. Access to PONDR® was provided by Molecular Kinetics (Indianapolis, IN, USA). VL-XT is copyright©1999 by the WSU Research Foundation, all rights reserved, and PONDR® is copyright©2004 by Molecular Kinetics, all rights reserved. Probabilities of coiled-coil formation by proteins were determined using COILS (<http://www.ch.embnet.org/software/COILS_form.html>) and PCOILS (<http://toolkit.tuebingen.mpg.de/pcoils>).

Recombinant proteins
--------------------

All recombinant proteins contained amino-terminal polyhistidine tags. Alleles of *bpaB* were named according to the replicon on which the gene is located, e.g. cp32-1 contains *bpaB*321, lp56 contains *bpaB*56, cp9-1 contains *bpaB9*, lp38 carries *bpaB38*, etc. For production of full-length recombinant BpaB321, BpaB56, BpaB9 and BpaB38, their respective genes were polymerase chain reaction (PCR)-amplified and cloned into pET200-TOPO (Invitrogen). Plasmids encoding truncated BpaB321 proteins were produced by sequence overlap extension PCR mutagenesis ([@B36]) of the full-length BpaB321 expression plasmid. Inserts of all recombinant plasmids were completely sequenced on both strands to confirm expected results. Recombinant EbfC was produced using a previously described plasmid ([@B21]). *Escherichia coli* strain Rosetta(DE3)(pLysS) (Invitrogen) was individually transformed with each plasmid. Production of recombinant proteins was induced by addition of isopropyl-β-[d]{.smallcaps}-galactopyranose (IPTG, final concentration 1 mM) to mid-exponential phase 37°C cultures, then incubated overnight with aeration at room temperature. Alternatively, *E. coli* were grown overnight at 37°C in 100 ml expansion broth (Zymo Research), inoculated into 500 ml over-expression broth (Zymo Research) the following day, then cultured for another 24 h at 37°C. Bacteria were harvested by centrifugation. Cells were resuspended in binding buffer (20 mM NaPO4, 1 M NaCl, 30 mM imidazole, pH 7.4), and bacteria lysed by sonication. Lysates were cleared by centrifugation at 15 000*g*, then injected onto a pre-equilibrated 5 ml HisTrap-HP column on an AKTA-FPLC with a UPC-900 absorbance monitor and a Frac920 fraction collector (all GE Healthcare). The column was washed with 15 column volumes of binding buffer, followed by linear gradient elution with imidazole concentrations steadily increasing from 30 to 750 mM. Aliquots of eluted fractions were analyzed for purity by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie brilliant blue staining. Proteins were then dialyzed against 50 mM Tris--HCl, pH = 7.5, 1 mM phenylmethanesulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT) and 10% (vol/vol) glycerol. Final protein concentrations were determined by bicinchoninic acid (BCA) protein assay (Pierce). Purified, dialyzed proteins were snap frozen in liquid nitrogen and stored at −80°C.

Electrophoretic mobility shift assays
-------------------------------------

A previously constructed recombinant plasmid containing B31 *erpAB1* 5′ non-coding DNA (including Operator 2) served as template for sequence overlap extension PCR mutagenesis of *erp* Operator 2 DNA ([@B21],[@B36]), deleting 20 bp from *erp* Operator 2 to yield pBLS672. The *erp* 5′ noncoding sequence of that mutant plasmid was completely sequenced on both strands to confirm expected results.

The wild-type *erp* Operator 2-containing plasmid was used as template for producing wild-type electrophoretic mobility shift assay (EMSA) probe b-WT and the labeled probes used in simultaneous EMSA studies which initially identified the high-affinity, initial binding site of BpaB competitor DNAs. Plasmid pBLS672 served as template for production of probe b-672. For each of these labeled probes, the upstream primer used had been modified with a biotin moiety on the 5′ end. For unlabeled DNA competitors, unmodified oligonucleotides were used. Amplification products were separated by agarose gel electrophoresis, the appropriate band excised, and DNA cleaned using Wizard SV gel purification systems (Promega). Prior to use in EMSA, the concentration of each probe was determined spectrophotometrically (A~260~ of 1.0 = 50 µg DNA/ml), then diluted to a concentration of 1 nM. EMSA reactions were performed in 20 µl total volumes, containing 2 fmol biotinylated DNA probe in 50 mM Tris--HCl (pH = 7.5), 1 mM dithiothreitol, 8 µl/ml protease inhibitor (Sigma, St. Louis, MO, USA), 2 µl/ml phosphatase inhibitor cocktail II (Sigma), 50 µg/ml bovine serum albumin, 10% glycerol, 40 ng/µl poly(dI--dC) (Sigma), and various concentrations of recombinant protein. Reaction mixes were incubated for 20 min at room temperature, followed by electrophoresis in pre-cast 6% acrylamide gels (Invitrogen) for 90 min at 100 V. DNAs were transferred to nylon membranes (Pierce), and cross-linked by exposure to ultraviolet (UV) light. Labeled DNAs were detected using chemiluminescent nucleic acid detection kits (Pierce) and exposure to Kodak Biomax film.

Radiolabeled EMSA probes r-40 and r-23 were produced from pairs of complimentary oligonucleotides either 40 or 23 bp in length, respectively ([Figure 1](#F1){ref-type="fig"}). Following are details on production of probe r-40. Probe r-23 was produced in exactly the same manner, except with use of oligonucleotides 23-F and 23-R. For probe r-40, two complimentary 40 base sequences, 40-F and 40-R, were synthesized. Oligonucleotide 40-F was 5′-end labeled using γ-^32^P-ATP (Perkin-Elmer) and T4 Kinase (New England Biolabs). The radiolabeled DNA was ethanol precipitated, resuspended in H~2~0, passed through a Sephadex 10 (Sigma) column and dialyzed in TE buffer, pH = 8. A 1.2-fold excess of the complementary oligomer, 40-R, was added to the radiolabeled 40-F oligomer. The DNAs were annealed by first incubating for 5 min in a boiling water bath, then the heat turned off and allowed to cool to ∼37°C (3--4 h). The resulting dsDNA was dialyzed with EMSA buffer. Varying concentrations of purified BpaB321 protein were added to 0.2 µM ^32^P-labeled r-40, and mixtures were equilibrated at 4°C for 4 h. Electrophoresis was carried out in an 8% polyacrylamide gel using low salt TAE buffer 0.8 M Tris and 0.02 M EDTA pH 7.6. Autoradiographic images were captured on storage phosphor screens (type GP, GE Healthcare) detected with a Storm phosphorimager and quantitated with Image-Quant software (GE Healthcare).

For studies to determine binding constants, a luminescent form of wild-type *erpAB* Operator 2 probe b-WT was produced. The upstream primer had been modified with an IRDye 700 fluorescent infrared dye at its 5′-end (LI-COR). Amplification products were separated by agarose gel electrophoresis, the appropriate DNA band excised, then cleaned as above. EMSAs were carried out as described previously. Luminescent DNA bands were detected using an Odyssey Infrared Imaging System (LI-COR). Disassociation constants (*K*~d~) for BpaB--DNA interactions were determined by comparing the signal strengths of bound and unbound DNA in each reaction. Signal strengths were normalized for each lane. Ratios of bound : free DNA were graphed in relation to the known concentrations of free protein \[P\], using Microsoft Excel. Since the ratios of free protein to DNA were extremely high, the binding of protein to DNA did not appreciably change the concentration of free protein ([@B37]) The disassociation constant was therefore calculated as the concentration of BpaB where the ratio of bound to free DNA = 1 ([@B22],[@B37; @B38; @B39]).

Analyses of DNA conformation
----------------------------

Five 150-bp DNA fragments, overlapping stepwise by 30-bp increments over a total of 250 bp, were produced by PCR, using the cloned *erpAB* insert of pBLS434a as template ([@B16],[@B22]). The upstream oligonucleotide primer for each DNA fragment was modified with a biotin moiety at the 5′ end. Natural curvature of the DNAs was analyzed by electrophoresis through 15% polyacrylamide gels and staining with ethidium bromide. EMSA using purified recombinant BpaB321 was performed as described previously.

RESULTS
=======

BpaB binds to *erp* Operator 2 DNA
----------------------------------

We previously reported that DNA-affinity chromatography using *erp* 5′ noncoding DNA and *B. burgdorferi* cytoplasmic extracts led to isolation of three different proteins ([@B21]). Subsequent mass spectrometric analyses of tryptic fragments of the largest, ∼22-kDa, *erp*-binding protein suggested it to be encoded by a gene located on the *B. burgdorferi* cp32 prophages (data not shown). These genes have been implicated in plasmid maintenance, and have been variously referred to as ORF-3, ORF-D, paralog family 49 or pfam01672 ([@B18],[@B19],[@B24],[@B26],[@B28],[@B40],[@B41]). Due to apparent functional similarities between the ∼22-kDa proteins encoded by these borrelial genes and the ParB/SopB proteins of other bacterial species, we named the borrelial proteins 'BpaB' (*[B]{.ul}*orrelial *[Pa]{.ul}*r*[B]{.ul}* analog). The validity of this proteomic identification of BpaB as an *erp*-binding protein was investigated by EMSA using labeled DNA probe b-WT, derived from the wild-type *erpAB1* locus ([Figure 1](#F1){ref-type="fig"}B), and recombinant BpaB allele 321, based on the *bpaB* gene sequence of *B. burgdorferi* strain B31 cp32-1. Incubation of probe b-WT with BpaB321 protein yielded slowly migrating EMSA bands, consistent with DNA-protein complexes ([Figure 2](#F2){ref-type="fig"}A). Preincubation of recombinant protein and DNA at room temperature, 4°C or 37°C made no significant differences in protein binding, so all subsequent EMSAs were performed at room temperature ([Figure 2](#F2){ref-type="fig"}A, lanes 2--4). BpaB specificity for *erp* Operator 2 DNA was assessed by competition EMSA using excess quantities of unlabeled DNAs derived from either *erp* 5′ DNA or from an unrelated source. Competitor C-100, which consists of part of *erp* Operator 2, partially inhibited formation of the protein--DNA complexes ([Figure 2](#F2){ref-type="fig"}A, lane 5). A 100-fold excess of unlabeled DNA identical in sequence to the labeled probe almost completely eliminated the protein--DNA complex bands ([Figure 2](#F2){ref-type="fig"}A, lane 6). However, addition of a 100-fold excess of unlabeled DNA derived from the promoter region of the unrelated *B. burgdorferi flaB* gene did not have any detectable effects on DNA--protein complex formation ([Figure 2](#F2){ref-type="fig"}A, lane 7). As additional controls, heating recombinant BpaB321 in a boiling water bath for 10 min prior to incubation with DNA, or addition of SDS (final concentration 10%) to the DNA--protein mixture prevented formation of the upper bands, consistent with compositions that include protein ([Figure 2](#F2){ref-type="fig"}A, lanes 8 and 9). Figure 2.Demonstration that BpaB binds specifically to *erp* Operator 2 DNA. (**A**) EMSA with labeled *erp* probe b-WT and purified recombinant protein based on the sequence of *bpaB* from *B. burgdorferi* strain B31 cp32-1 (BpaB321). Lane 1 lacked added BpaB321, while 0.12 µM recombinant protein was added to the other lanes. (Lanes 2--4) Pre-incubation of DNA and protein at room temperature, 4°C and 37°C, respectively. (Lanes 5--7) DNA and protein mixtures were preincubated with 100-fold excesses of unlabeled competitor DNAs C-100, unlabeled-WT, or *flaB*, respectively. (Lane 8) BpaB321 was heated in a boiling water bath for 10 min prior to mixture with DNA. (Lane 9) 10% SDS, final concentration, was added to the DNA--protein mixture prior to EMSA. (**B**) Supershift EMSA using BpaB-directed antibodies. Lane 1 contained only DNA, lane 2 contained DNA plus 0.19 µM BpaB321, and lanes 3--10 contained the same concentrations of DNA and BpaB321 plus increasing concentrations of anti-BpaB321 polyclonal antiserum.

Confirmation that the slowly migrating bands consisted of DNA--BpaB complexes was obtained by antibody super-shift studies. Addition of increasing concentrations of polyclonal rabbit antiserum raised against and specific for BpaB led to the appearance of EMSA bands with even slower mobilities, consistent with DNA--BpaB--antibody complexes ([Figure 2](#F2){ref-type="fig"}B). Antibodies in the absence of BpaB did not affect levels of free DNA (data not shown).

Initial EMSAs, such as those shown in [Figure 2](#F2){ref-type="fig"}, indicated multiple BpaB--DNA complexes. The natures of these multiple complexes were investigated by additional EMSA, using a constant concentration of *erpAB1* Operator 2 DNA and increasing amounts of BpaB321. These analyses revealed formation of a single protein--DNA complex at low concentrations of BpaB321, with additional, more slowly migrating complexes forming as protein concentrations were increased ([Figure 3](#F3){ref-type="fig"}A). At the higher concentrations of BpaB321, the more rapidly migrating DNA--protein complexes disappeared. Additional studies described below revealed that this pattern was due to initial binding of a BpaB protein to a specific site on the DNA, with that bound protein facilitating the binding of additional BpaB molecules. Figure 3.EMSA using labeled probe b-WT and increasing concentrations of recombinant BpaB proteins based on sequences of B31 plasmids cp32-1, lp56, cp9-1 and lp38. For all EMSAs, lane 1 contained DNA without protein. (**A**) Lanes 2--12 contained in addition 0.033, 0.066, 0.099, 0.13, 0.17, 0.20, 0.23, 0.26, 0.30, 0.33 and 0.40 µM recombinant BpaB321 protein, respectively. (**B**) Lanes 2--12 contained 0.0048, 0.012, 0.024, 0.048, 0.097, 0.15, 0.19, 0.24, 0.29, 0.34 and 0.39 µM recombinant BpaB56 protein, respectively. (**C**) Lanes 2--12 contained 0.084, 0.17, 0.25, 0.34, 0.42, 0.50, 0.59, 0.67, 0.75, 0.84 and 1.00 µM recombinant BpaB9 protein, respectively. (**D**) Lanes 2--12 contained 0.069, 0.14, 0.21, 0.28, 0.35, 0.42, 0.48, 0.55, 0.62, 0.69 and 0.83 µM recombinant BpaB38 protein, respectively. Note that some of the higher-order DNA--protein complexes do not always resolve crisply, and appear faint or as smears in EMSAs \[e.g. the upper EMSA bands in lane 12 of (C)\].

Based upon the disappearance of free probe with increasing concentrations of BpaB321, a *K*~d~ value of 190 nM was calculated for the binding of protein to free *erp* Operator 2 DNA. This is obviously an underestimate of the protein's affinity for free DNA, since analyses necessarily included BpaB binding to DNA to which other BpaB molecules had previously attached.

BpaB proteins from different cp32 family members bind the same DNA sequence
---------------------------------------------------------------------------

The BpaB proteins encoded by the different naturally occurring cp32 family members share ∼ 35--70% amino acid sequence identities ([Figure 4](#F4){ref-type="fig"}). As discussed previously and illustrated in [Figure 1](#F1){ref-type="fig"}A, the Operator 2 sequences of all known *erp* loci are highly similar. This suggested that a protein which can bind a sequence within one *erp* locus' Operator 2 would probably be able to bind the Operator 2 regions of other *erp* loci, as is the case with EbfC ([@B21],[@B22]). This hypothesis predicts that since BpaB from cp32-1 binds *erp* Operator 2 DNA, then BpaB proteins encoded by other cp32 family members will also do so. Figure 4.Alignments of the predicted amino acid sequences of BpaB proteins encoded by *B. burgdorferi* B31 cp32 family members, and by the strain B31 plasmid lp38. Identical residues found in the majority of proteins are boxed and shaded. Gaps introduced to maximize homology are indicated by dashes. The amino terminus of protein ΔN-BpaB321 and the carboxy-termini of proteins ΔC1-BpaB321 and ΔC2-BpaB321 are indicated.

This question was first addressed by producing and purifying a recombinant BpaB protein derived from the *bpaB* allele encoded by the cp32 family member lp56 (BpaB56). EMSA using cp32-1-derived DNA and BpaB56 yielded banding patterns similar to those obtained when using BpaB321 ([Figure 3](#F3){ref-type="fig"}B). The *K*~d~ value of recombinant BpaB56 binding to this DNA was calculated to be 220 nM.

The small cp9-1 plasmid of *B. burgdorferi* strain B31 is a naturally occurring cp32-derivative that had undergone extensive mutations prior to isolation of the bacterium from nature ([@B18]). cp9-1 lacks an *erp* locus, but does encode a BpaB paralog. This protein's predicted sequence is \<50% identical to the other cp32 family members' BpaB paralogs ([Figure 4](#F4){ref-type="fig"}). It is, however, well conserved in the carboxy-terminal region that we identified as being involved with binding to *erp* Operator 2 DNA (see below). We therefore produced a recombinant protein based on the cp9-1 sequence, BpaB9. This recombinant protein also yielded a laddered banding pattern with cp32-1-derived *erp* Operator 2 DNA ([Figure 3](#F3){ref-type="fig"}C). The *K*~d~ value of recombinant BpaB9 binding to this DNA fragment was calculated to be 530 nM.

All but two of the naturally occurring plasmids of strain B31 contain a *bpaB* gene ([@B18],[@B29]). Having found that the BpaB proteins encoded by cp32-1, lp56 and cp9-1 all bind *erpAB1* Operator 2 DNA, the obvious next step was to examine the BpaB of a borrelial plasmid that is not related to the cp32 family ([@B18]). To that end, a recombinant protein was produced based on the *bpaB* allele of the 38-kb linear plasmid lp38, BpaB38 ([Figure 4](#F4){ref-type="fig"}). Unlike the cp32 family member BpaB proteins, BpaB38 was not able to bind *erp* Operator 2 DNA ([Figure 3](#F3){ref-type="fig"}D). The recombinant BpaB38 was produced and purified two different times, from separately transformed *E. coli* colonies, to control for possible denaturation during purification, yet the same result was obtained from both preparations.

Mapping the initial BpaB-binding site within *erp* Operator 2
-------------------------------------------------------------

To narrow down the high-affinity BpaB-binding site, additional, simultaneous EMSAs were performed. In one set of studies, seven different biotin-labeled DNA probes were produced from *erpAB1* 5′ DNA, each using the same downstream oligonucleotide primer paired with one of seven distinct upstream primers ([Figure 5](#F5){ref-type="fig"}A, upper 7 sequences). Being of different sizes, each DNA migrated at a different rate under PAGE. Equimolar amounts of all seven DNA probes were simultaneously incubated with various concentrations of BpaB321, then separated by PAGE. BpaB321 bound to the largest DNA probe at much lower protein concentrations than it did to the six shorter probes, indicating that the largest probe contained sequences necessary for initial high-affinity binding of BpaB, while the shorter probes lacked those bases ([Figure 5](#F5){ref-type="fig"}B). The same procedure was performed using another set of seven labeled probes, this time produced with the same upstream primer and different downstream primers ([Figure 5](#F5){ref-type="fig"}A, lower 7 sequences). The longest five of these probes bound BpaB321, indicating that they contained sequences for BpaB-binding that were lacking from the two smaller probes ([Figure 5](#F5){ref-type="fig"}C). Comparisons of BpaB-binding activities and the various sizes of probes used in these studies indicated that DNA probe size did not itself have an appreciable effect upon the results. These analyses demonstrated the presence of a high-affinity binding-site for BpaB within a region of *erp* Operator 2 DNA that overlaps EbfC-binding site I ([Figures 1](#F1){ref-type="fig"} and [5](#F5){ref-type="fig"}A). The identified DNA region is consistent with additional analyses described below. Figure 5.Identification of the high-affinity BpaB-binding site in *erp* Operator 2, by use of simultaneous titration of multiple probes with increasing concentrations of BpaB321. In this method, several DNAs that overlap in sequence were simultaneously incubated with protein, then subjected to EMSA. These DNAs which contain the high-affinity protein binding site were preferentially bound by lower concentrations of protein, and signals corresponding with those free DNA disappeared soonest. (**A**) Sequences of labeled DNA probes used in simultaneous EMSAs. Asterisks indicate DNAs preferentially bound by BpaB. The --35 sequence of the *erpAB* promoter and the two consensus EbfC-binding sites are indicated by underlining. The upper seven nested DNAs were anchored 51 bases downstream of the *erpAB* transcription start site, and EMSA data are illustrated in (**B**). The lower seven nested DNAs were anchored at bp --174 relative to the start of *erpAB* transcription, and EMSA data are illustrated in (**C**). The sequence contained in all DNAs that preferentially bound BpaB but absent from lower-affinity DNAs is indicated by a thick horizontal bar. (B) Simultaneous EMSA of recombinant BpaB321 with the upper seven DNAs of (A). Lane 1 contains only the DNAs. Lanes 2--12 contain DNAs plus increasing concentrations of recombinant BpaB321. Quantification of signal strengths indicated that BpaB bound preferentially to the largest DNA (marked with an arrowhead): in lanes 9, 10 and 12, the proportion of free DNA for this probe was 21, 0.10 and 0% of lane 1, respectively, while that of the next largest probe was 52, 13 and 10% of lane 1, respectively. (C) Simultaneous EMSA of recombinant BpaB321 with the lower seven DNAs of (A). Lane 1 contains only the DNAs. Lanes 2--12 contain DNAs plus increasing concentrations of recombinant BpaB321. Quantification of signal strengths indicated that BpaB bound preferentially to the five largest DNAs (marked with arrowheads): in lanes 7, 8 and 9, the proportion of free DNA for the largest probe was 16, 10 and 0% of lane 1, respectively, while that of the smallest probe was 75, 55 and 43% of lane 1, respectively.

Binding of a protein often alters the conformation of DNA, and protein-induced bending may be detected by EMSA. To explore whether BpaB-binding distorts DNA conformation, and to further define the location of initial BpaB-binding in *erp* Operator 2 DNA, we utilized a series of five identically sized DNA fragments of *erpAB1* 5′ DNA that overlapped each other by 30-bp increments ([Figure 6](#F6){ref-type="fig"}A). PAGE of the free DNAs indicate that *erpAB1* 5′ DNA contains a naturally occurring bend near the −10 site of the promoter ([Figure 6](#F6){ref-type="fig"} and reference 22). Addition of BpaB, at a concentration sufficient to produce a single protein--DNA complex EMSA band, yielded signals indicative of bending centered within DNA fragment 3 ([Figure 6](#F6){ref-type="fig"}B). The center of that DNA fragment lies near EbfC-binding site I ([Figure 6](#F6){ref-type="fig"}A), indicating a location for the high-affinity, initial BpaB-binding site consistent with the results obtained from the simultaneous EMSA studies described earlier. Figure 6.Binding of BpaB changes DNA conformation. (**A**) Sequence of the 5′ end of the *erpAB1* locus (top line) and five biotinylated 150-bp fragments of that DNA (probes 1 to 5). Arrowhead under the panel indicates the center of probe 3. (**B**) Comparisons of mobilities of free probes 1--5 and those probes bound by BpaB321. Numbers above each lane indicate the labeled probe being analyzed. Note that free probe 5 migrates the slowest, indicative of a naturally occurring bend near the center of that DNA ([@B22]). Binding of BpaB321 resulted in probe 3 migrating the slowest, indicating an induced change in DNA conformation.

Additional EMSA studies further indicated this region of DNA to be critical for initial BpaB-binding to *erp* Operator 2. Site-directed mutagenesis was utilized to produce a labeled probe, b-672, that lacked 20 bp of *erpAB1* Operator 2 but was otherwise identical to the previously used probe b-WT ([Figure 1](#F1){ref-type="fig"}B). Simultaneous EMSA using probes b-672 and b-WT demonstrated appreciable BpaB binding to the wild-type DNA, but not to the mutant DNA ([Figure 7](#F7){ref-type="fig"}A). In the illustrated EMSA, the highest concentration of BpaB assayed bound almost all the free b-WT probe, but did not bind even half of the free mutant b-672 probe. EMSA using probe b-672 alone, with concentrations of BpaB similar to those above, detected very faint shifted bands upon extended film exposures, but due to the weakness of interactions, a binding affinity could not be calculated (data not shown). These results indicate that the 20 bp deleted from b-672 contain nucleotides necessary for high-affinity binding of BpaB. Noting that the deletion of these 20 bp prevented formation of any readily detectable BpaB--DNA complexes, these experiments also demonstrated that formation of the other BpaB--DNA complexes observed with wild-type *erp* DNAs require formation of the initial DNA--protein complex. Figure 7.Confirmation of the initial BpaB-binding site in *erp* Operator 2 (**A**) Simultaneous EMSA using wild-type recombinant BpaB321 protein and both biotin-labeled wild-type *erpAB1* probe b-WT and b-672. Probe b-672 is identical to b-WT except for deletion of 20 bp ([Figure 1](#F1){ref-type="fig"}). Lane 1 contained only DNA. Lanes 2--12 contained BpaB321 at concentrations of 0.086, 0.18, 0.26, 0.35, 0.44, 0.53, 0.61, 0.70, 0.79, 0.86 and 1.1 µM, respectively. (**B**) EMSA using the radioactively labeled 40 bp probe r-40 ([Figure 1](#F1){ref-type="fig"}). Lane 1 contained only DNA. Lanes 2--20 contained BpaB321 at concentrations of 0.40, 0.80, 1.0, 1.2, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 7.0, 10, 15, 20, 25, 30, 40 and 50 µM, respectively. (**C**) EMSA using the radioactively labeled 23-bp probe r-23, which encompasses the 20-bp sequence present in b-WT but absent from b-672 (see [Figure 1](#F1){ref-type="fig"}). Lane 1 contained only DNA. Lanes 2--17 contained BpaB321 at concentrations of 0.40, 0.80, 1.0, 1.2, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 7.0, 10, 15, 20 and 30 µM, respectively.

A second series of EMSAs utilized a 40-bp probe, r-40, which includes the DNA regions identified by the above-described experiments ([Figure 7](#F7){ref-type="fig"}B). The *K*~d~ of recombinant BpaB321 binding to probe r-40 was calculated to be 20 µM. At most, three protein--DNA species were detected by EMSA when using probe r-40, in contrast with the six complexes observed when using the 125-bp probe b-WT ([Figure 3](#F3){ref-type="fig"}A). These data support the hypothesis that the multiple complexes observed in BpaB--DNA EMSAs are due to multiple protein--DNA interactions.

The 23-bp probe, r-23, which incorporates the sequence deleted from probe b-672, was used for additional EMSAs. Recombinant BpaB321 bound to this small piece of DNA with a *K*~d~ of 3.2 µM ([Figure 7](#F7){ref-type="fig"}C). Thus, this 23-bp segment of *erp* Operator 2 contains a nucleotide sequence sufficient for high-affinity binding of BpaB. This result is consistent with the above-described studies with probe b-672 ([Figure 7](#F7){ref-type="fig"}A) and with the simultaneous EMSAs using overlapping DNA probes ([Figure 5](#F5){ref-type="fig"}).

Identification of the DNA-binding domain of BpaB
------------------------------------------------

Comparisons of the BpaB proteins encoded by cp32 family members show limited identities in the amino-terminal third ([Figure 4](#F4){ref-type="fig"}). Site-directed mutagenesis of the cp32-1-encoded BpaB was employed to produce truncated recombinant protein ΔN-BpaB321, which lacks the first 53 residues. EMSA using the truncated protein did not show significantly different results from those found with the full-length protein ([Figure 8](#F8){ref-type="fig"}A). Addition of increased concentrations of ΔN-BpaB321 to EMSA reactions yielded reduced amounts of free probe DNA and increased laddering of protein--DNA bands. These results indicate that the amino-terminal third of BpaB is not required for either initial or subsequent binding of DNA. Figure 8.EMSAs using wild-type *erpAB1* DNA and truncated BpaB321 proteins. For all panels, lane 1 contained DNA without protein. **(A)** Lanes 2--12 contained 0.013, 0.026, 0.039, 0.052, 0.065, 0.078, 0.090, 0.10, 0.12, 0.13 and 0.16 µM recombinant ΔN-BpaB321, respectively. **(B)** Lanes 2--12 contained 0.078, 0.016, 0.023, 0.031, 0.039, 0.047, 0.055, 0.062, 0.070, 0.078 and 0.094 µM recombinant ΔC1-BpaB321 respectively. **(C)** Lanes 2--12 contained 0.0075, 0.015, 0.023, 0.030, 0.038, 0.045, 0.053, 0.060, 0.068, 0.075 and 0.090 µM recombinant ΔC2-BpaB321, respectively.

Truncated protein ΔC1-BpaB321 was next produced, lacking the carboxy-terminal 22 amino acids ([Figure 4](#F4){ref-type="fig"}). EMSAs using that recombinant protein were not appreciably different from those using full-length BpaB321 ([Figure 8](#F8){ref-type="fig"}B).

A third truncated protein was produced, ΔC2-BpaB321, which lacks the carboxy-terminal 58 amino acids of BpaB321 ([Figure 4](#F4){ref-type="fig"}). EMSA using this truncated protein revealed significantly weakened DNA binding ([Figure 8](#F8){ref-type="fig"}C). Laddering was not seen, even at high protein concentrations. A single, weak, slowly migrating signal was observed, but diminution of the free DNA was not detected and so the binding affinity of ΔC2-BpaB321 was too weak to be determined. Protein ΔC2-BpaB321 was induced and purified two separate times, with both preparations giving the same results, indicating that failure to bind DNA was unlikely to have been due to denaturation during purification. Hence, the 36 amino acid region absent from ΔC2-BpaB321 but present in ΔC1-BpaB321 is necessary for high-affinity DNA binding. Modeling analyses of BpaB molecules predicted these proteins to be comprised of multiple α-helices, with the 36-residue region involved in high-affinity binding predicted to be a disordered region bridging two α-helices (data not shown). Additional analyses to identify specific residues of BpaB involved with binding to *erp* Operator 2 and with protein--protein interactions are ongoing.

BpaB and EbfC compete for binding to *erp* Operator 2 DNA
---------------------------------------------------------

The above-described results, combined with previous data ([@B21],[@B22]), indicate that both BpaB and EbfC bind to adjacent or overlapping DNA sequences of *erp* Operator 2 ([Figure 1](#F1){ref-type="fig"}). To determine the effects each protein has upon DNA-binding by the other, EMSAs were performed in which labeled *erp* Operator 2 DNA was preincubated with a fixed amount of one protein, then increasing concentrations of the other protein were added.

When the concentration of BpaB321 was held constant, increasing concentrations of EbfC led to reduced levels of free DNA and increased levels of EbfC--DNA complexes ([Figure 9](#F9){ref-type="fig"}A). There were not any detectable changes observed in band intensities of any of the BpaB--DNA complexes. Measured ratios of free DNA signal to BpaB--DNA complex 1 signal diminished from 3.9 : 1 in lane 4 to 0.57 : 1 in lane 12 of [Figure 9](#F9){ref-type="fig"}A. Thus, EbfC preferentially bound to free *erp* Operator 2 DNA, as opposed to previously formed BpaB--DNA complexes.

In other studies, the DNA probe was preincubated with a constant level of EbfC, then BpaB concentrations were increased. The signal strengths of EbfC--DNA complexes and free DNA all decreased, while signal strengths of BpaB--DNA complexes increased ([Figure 9](#F9){ref-type="fig"}B). Thus, under these experimental conditions, recombinant BpaB321 can drive recombinant EbfC off Operator 2 DNA. Together, these competition EMSAs indicate that BpaB and EbfC compete for *erp* Operator 2 DNA. Figure 9.EbfC and BpaB compete for binding to *erp* Operator 2. **(A)** EMSAs in which the concentration of BpaB321 was held constant while increasing concentrations of EbfC were added. (Lane 1) Labeled probe b-WT alone. (Lanes 2 and 3) Probe b-WT preincubated with 2.05 and 2.89 µM recombinant EbfC or BpaB321, respectively. (Lanes 4--12) Probe b-WT preincubated with 0.97 µM recombinant BpaB321, plus EbfC at concentrations of 0.27, 0.51, 1.03, 1.54, 2.05, 2.56, 3.08, 3.59 and 4.10 µM, respectively. Compositions of EMSA bands are indicated to the right of the panel. Asterisks indicate nonspecific DNA binding by EbfC observed at high concentrations of that protein (our unpublished data). Ratios of free DNA to BpaB--DNA complex 1 in lanes 4 through 12 were 3.9 : 1, 3.5 : 1, 2.7 : 1, 2.1 : 1, 1.4 : 1, 1.1 : 1, 1.1 : 1, 0.86 : 1 and 0.57 : 1, respectively, with the BpaB--DNA complex signals remaining constant, indicating that EbfC preferentially bound to free DNA. Quantification of signal intensities indicated that the proportion of EbfC--DNA complexes steadily increased with addition of EbfC protein, and that total of signal strengths remained constant across the EMSA gel. **(B)** EMSAs in which the concentration of EbfC was held constant while increasing concentrations of BpaB321 were added. (Lane 1) Labeled probe b-WT alone. (Lanes 2 and 3) Probe b-WT pre-incubated with 0.2 and 0.3 µM recombinant EbfC or BpaB321, respectively. (Lanes 4--12) Probe b-WT preincubated with 0.3 µM recombinant BpaB321, plus EbfC at concentrations of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1 µM, respectively. Compositions of EMSA bands are indicated to the right of the panel. The asterisk indicates nonspecific DNA binding by EbfC observed at high concentrations of that protein (our unpublished data). Quantification of signal strengths indicated that proportions of free DNA and DNA bound by EbfC decreased as additional BpaB was added, while proportions of BpaB--DNA complexes increased.

DISCUSSION
==========

Previous studies by our laboratory indicated that a conserved region immediately 5′ of *erp* promoters, Operator 2, is critical for repression of *erp* transcription. We have now identified two different *B. burgdorferi* proteins that bind specific DNA sequences within *erp* Operator 2. The high-affinity BpaB-binding sequence is adjacent to and possibly overlaps the high-affinity EbfC-binding sites. Dual protein binding assays indicated that both BpaB and EbfC preferentially bind to free DNA, with no evidence of both proteins binding DNA simultaneously. Thus, it is possible that either BpaB or EbfC is a repressor of *erp* transcription, while the other protein functions as an activator/anti-repressor by competing for *erp* Operator 2 DNA. This hypothesis is currently being tested through additional studies to correlate cellular BpaB and EbfC levels with *erp* transcription.

Addition of low concentrations of BpaB to EMSA reactions produced a single DNA--protein complex, while addition of increasing concentrations of BpaB yielded increasing numbers of BpaB--DNA complexes. Deletion of 20 bp within *erp* Operator 2 significantly inhibited formation of any BpaB--DNA complex, indicating that this small region must contain sequences critical for all of the BpaB--DNA complexes formed with wild-type *erp* Operator 2 DNA. Thus, we conclude that BpaB initially forms a high-affinity complex with a specific sequence within *erp* Operator 2, and that subsequent binding of BpaB to *erp* DNA is dependent upon that initial binding. Presumably, protein--protein interactions between BpaB molecules stabilize binding to non-preferred DNA sequences. Without the specific DNA sequence, initial BpaB binding was impaired, and so was the binding of additional molecules. The binding of subsequent BpaB proteins from a nucleation site is similar to what has been demonstrated for several other bacterial DNA-binding proteins, such as the spreading phenomena of some ParB proteins and *E. coli* H-NS ([@B23],[@B30; @B31; @B32; @B33],[@B42]).

The current studies demonstrated that BpaB proteins encoded by the cp32 family members cp32-1, lp56 and cp9-1 all bound to *erp* Operator 2 DNA, and all produced multiple DNA--protein complexes. Analyses of mutant proteins indicated that a 36 amino acid region in the carboxy-terminal half of BpaB contains residues necessary for specific DNA binding. The region, between 22 and 58 residues from the carboxy-terminus, is highly conserved among all cp32 family BpaB proteins. These data strongly suggest that all BpaB proteins encoded by cp32 family members can bind *erp* Operator 2 DNA.

In contrast, the BpaB protein encoded by the *B. burgdorferi* B31 lp38 replicon did not bind *erp* Operator DNA. This result is consistent with the low degrees of similarities in the carboxy-terminal regions of lp38 BpaB and the cp32-encoded proteins. These data also indicate that non-cp32 replicons such as lp38 are unlikely to directly influence *erp* transcription.

BpaB plays a role(s) in *B. burgdorferi* replicon maintenance ([@B24; @B25; @B26; @B27]). Almost all borrelial replicons contain a *bpaB* adjacent to gene bearing strong similarity to the *parA/sopA* genes of other bacterial species' replicons. Each replicon within an individual *B. burgdorferi* cell carries a distinctively different pair of *parA* homolog and *bpaB* genes, and those pairings appear to coincide with incompatibility groups ([@B18],[@B24],[@B28]). These data suggest that, even though BpaB sequences are dissimilar from characterized ParB proteins of other bacterial plasmids, BpaB may perform segregation functions similar to those of typical ParBs. Bacterial ParB proteins are site-specific DNA-binding proteins with affinities for *parS* DNA sequences on their replicons, and interactions between ParB, ParA and *parS* play roles in replicon segregation. It is possible that *erp* Operator 2 regions contain the *parS* homologue of cp32 elements, although we feel this to be unlikely due to ability of all tested cp32 family-encoded BpaB proteins to bind that DNA. Alternatively, *parS* may be located elsewhere on these replicons, while the DNA sequence within *erp* Operator 2 directs binding of additional BpaB molecules for another reason, such as regulation of *erp* transcription. Studies are ongoing to determine the consensus high-affinity binding sequence of cp32-encoded BpaB proteins, and where else these proteins bind on the replicons.

In conclusion, a new DNA-binding protein of *B. burgdorferi* was discovered, and was demonstrated to bind with high affinity to a DNA sequence within *erp* Operator 2. Binding of BpaB at that site led to DNA-bending and to the binding of additional BpaB molecules. The high-affinity BpaB-binding site is adjacent to or overlaps the high-affinity EbfC-binding sites, and those two proteins were found to compete for binding to *erp* Operator 2 DNA. Since that region of DNA is required for control of *erp* operon transcription ([@B20]), the present studies suggest that cellular levels of free BpaB and EbfC may contribute to regulation of *erp* gene expression.
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